Literature DB >> 1384319

Autoimmune neutropenia following peripheral blood stem cell transplantation.

T R Klumpp1, J H Herman, J S Macdonald, M K Schnell, M Mullaney, K F Mangan.   

Abstract

The differential diagnosis of unexpected neutropenia following bone marrow transplantation includes several potentially life-threatening complications including graft rejection, overwhelming infection, relapse of the underlying neoplasm, and intrinsic graft failure. However, a number of recent reports document that the differential diagnosis also includes autoimmune neutropenia, which, although potentially life-threatening, often responds well to corticosteroids or splenectomy. Autoimmune neutropenia has been reported following both autologous and allogeneic bone marrow transplantation. Herein we report a 31-year-old woman who developed a rapidly falling neutrophil count 11 days following peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. A laboratory evaluation supported a diagnosis of autoimmune neutropenia, and the neutropenia resolved following treatment with steroids and granulocyte-colony stimulating factor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384319     DOI: 10.1002/ajh.2830410313

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Severe autoimmune neutropenia associated with acute autoimmune hepatitis.

Authors:  Ahmad M Wehbe; Birgir Johannsson; Thomas J Raife; Michelle Bleile; Adam Bell; Brian R Curtis; Thorvardur R Halfdanarson
Journal:  Int J Hematol       Date:  2010-04-02       Impact factor: 2.490

2.  Splenectomy for severe autoimmune cytopenias after allogenic stem cell transplantation: case report.

Authors:  Irena Proleznik; Hugh Grant Prentice; Joze Pretnar; Samo Zver; Peter Cernelc
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

Review 3.  Primary and secondary autoimmune neutropenia.

Authors:  Franco Capsoni; Piercarlo Sarzi-Puttini; Alberto Zanella
Journal:  Arthritis Res Ther       Date:  2005-08-31       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.